Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Keros Therapeutics (KROS) EBITDA Margin (2019 - 2025)

Keros Therapeutics filings provide 6 years of EBITDA Margin readings, the most recent being 5072.79% for Q4 2025.

  • On a quarterly basis, EBITDA Margin fell 1555586.0% to 5072.79% in Q4 2025 year-over-year; TTM through Dec 2025 was 27.66%, a 17566650.0% decrease, with the full-year FY2025 number at 27.69%, changed N/A from a year prior.
  • EBITDA Margin hit 5072.79% in Q4 2025 for Keros Therapeutics, down from 107.87% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 10483.07% in Q4 2024 to a low of 541000.0% in Q3 2023.
  • Median EBITDA Margin over the past 5 years was 219.16% (2025), compared with a mean of 54468.25%.
  • Biggest five-year swings in EBITDA Margin: soared 52588222bps in 2024 and later tumbled -1555586bps in 2025.
  • Keros Therapeutics' EBITDA Margin stood at 27.18% in 2021, then plummeted by -393bps to 134.03% in 2022, then crashed by -24137bps to 32486.01% in 2023, then soared by 132bps to 10483.07% in 2024, then crashed by -148bps to 5072.79% in 2025.
  • The last three reported values for EBITDA Margin were 5072.79% (Q4 2025), 107.87% (Q3 2025), and 219.16% (Q2 2025) per Business Quant data.